Clinical trial
Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary…
NCT00262080 · Shire, Industry · Completed
Key facts
| NCT number | NCT00262080 |
|---|---|
| Title | Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE) |
| Official title | A Double-blind, Placebo-controlled Study (72 Patients, Randomized 1:1) Followed by a Repeat-dosing Phase to Assess the Efficacy and Safety of DX-88 (Ecallantide; Recombinant Plasma Kallikrein Inhibitor) for the Treatment of Acute Attacks of Hereditary Angioedema |
| Lead sponsor | Shire, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hereditary Angioedema (HAE) |
| Intervention type | Drug |
| Interventions | ecallantide, Phosphate Buffer Saline (PBS) |
| Enrollment | 91 |
| Start date | Dec 31, 2005 |
| Primary completion | Dec 31, 2005 |
| Completion | Feb 28, 2007 |
| First posted | Dec 6, 2005 |
| Last update posted | Jun 11, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: